

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>PEAD PHILIP M</u> (Last) (First) (Middle) 222 MERCHANDISE MART PLAZA SUITE 2024 (Street) CHICAGO IL 60654 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. [MDRX]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>Chr of the Bod & Mem sen Mana</u>
	3. Date of Earliest Transaction (Month/Day/Year) 08/24/2010	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	08/24/2010		A		189,676	A	(1)	189,676	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Option to buy	\$12.32	08/24/2010		A		540,000		08/24/2010 ⁽²⁾	05/14/2016	Common Stock	540,000	(3)	540,000	D	
Performance Stock Units ⁽⁴⁾	\$0.00	08/24/2010		A		30,000 ⁽⁵⁾		(4)	03/15/2013	Common Stock	30,000 ⁽⁵⁾	(6)	30,000 ⁽⁵⁾	D	

Explanation of Responses:

- Received pursuant to the Agreement and Plan of Merger, dated as of June 9, 2010, among Allscripts-Misys Healthcare Solutions, Inc. (which has changed its name to Allscripts Healthcare Solutions, Inc.) ("Allscripts"), Arsenal Merger Corp. and Eclipsys Corporation (the "Merger Agreement") in exchange for 136,179 shares held directly, and 21,884 Deferred Stock Units of Eclipsys Corporation. On the effective date of the merger, the closing price of Allscripts Healthcare Solutions, Inc. common stock was \$17.47 per share.
- As of the effective time of the merger, the options were fully vested pursuant to the terms of Mr. Pead's employment agreement.
- Received pursuant to the Merger Agreement in exchange for a stock option to acquire 450,000 shares of Eclipsys Corporation common stock for \$14.78 per share.
- Each Performance Stock Unit ("PSU") represents a contingent right to receive a number of shares of Allscripts common stock ranging from zero to 2.7, depending upon Eclipsys' total shareholder return ("TSR") compared to the TSRs of a group of pre-selected companies in the healthcare technology and software industries over a performance period commencing on March 15, 2010 ending on August 24, 2010, the effective date of the merger.
- Assumes Eclipsys' TSR was at the 50th percentile of the comparison group. Actual payout for PSUs can range from 0% to 270% of the amount shown depending upon relative TSRs for the performance period.
- Received pursuant to the Merger Agreement in exchange for an identical number of performance share units payable in Eclipsys Corporation common stock.

/s/ Kathie Kittner by power of attorney for Philip M. Pead 08/26/2010

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.